Loading...
•
Jun 30, 2023
Zentalis Q2 2023 Earnings Report
Reported financial results for the quarter ended June 30, 2023, and highlighted recent corporate accomplishments.
Key Takeaways
Zentalis Pharmaceuticals reported strong azenosertib data and a solid cash position after raising approximately $250.0 million in gross proceeds from a recent follow-on offering, extending cash runway into 2026. Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients. The company is well positioned to advance its program with its current cash reserves.
Azenosertib monotherapy achieved an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients who received intermittent dosing.
Identified azenosertib monotherapy RP2D, which more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations.
Presented positive Phase 1b azenosertib + chemotherapy data in ovarian cancer at ASCO, demonstrating encouraging anti-tumor activity and strong tolerability profile with intermittent dosing.
Raised approximately $250.0 million in gross proceeds from recent follow-on offering, extending cash runway into 2026.
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of June 30, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...